Blackhawk Capital Partners LLC. Has $1.61 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Blackhawk Capital Partners LLC. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 48.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,521 shares of the company's stock after purchasing an additional 4,750 shares during the period. Blackhawk Capital Partners LLC.'s holdings in Neurocrine Biosciences were worth $1,606,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Crossmark Global Holdings Inc. grew its holdings in shares of Neurocrine Biosciences by 3.8% during the 1st quarter. Crossmark Global Holdings Inc. now owns 8,785 shares of the company's stock valued at $972,000 after acquiring an additional 320 shares in the last quarter. IFM Investors Pty Ltd boosted its holdings in Neurocrine Biosciences by 2.5% in the first quarter. IFM Investors Pty Ltd now owns 19,459 shares of the company's stock worth $2,242,000 after purchasing an additional 469 shares in the last quarter. GF Fund Management CO. LTD. lifted its position in Neurocrine Biosciences by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,593 shares of the company's stock worth $287,000 after acquiring an additional 467 shares during the last quarter. Vontobel Holding Ltd. boosted its holdings in Neurocrine Biosciences by 17.8% during the first quarter. Vontobel Holding Ltd. now owns 9,943 shares of the company's stock valued at $1,100,000 after acquiring an additional 1,501 shares during the period. Finally, Smallwood Wealth Investment Management LLC bought a new stake in Neurocrine Biosciences during the first quarter valued at about $34,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 9,613 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total value of $1,157,212.94. Following the sale, the director owned 514,596 shares of the company's stock, valued at $61,947,066.48. This trade represents a 1.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jude Onyia sold 20,362 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $130.13, for a total value of $2,649,707.06. Following the completion of the sale, the insider directly owned 18,289 shares in the company, valued at $2,379,947.57. This represents a 52.68% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 59,975 shares of company stock worth $7,112,920. Corporate insiders own 4.80% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on NBIX. UBS Group upped their price objective on shares of Neurocrine Biosciences from $152.00 to $174.00 and gave the company a "buy" rating in a research report on Wednesday. HC Wainwright dropped their price target on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating for the company in a research report on Tuesday, April 22nd. Guggenheim increased their price target on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $145.00 price objective on shares of Neurocrine Biosciences in a report on Monday, June 2nd. Finally, JPMorgan Chase & Co. raised their price objective on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a report on Wednesday, March 26th. Three equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $163.05.

Neurocrine Biosciences Stock Performance

NBIX stock traded up $4.77 during midday trading on Wednesday, hitting $133.51. 1,261,236 shares of the company's stock were exchanged, compared to its average volume of 1,144,525. The stock's fifty day moving average price is $122.63 and its 200-day moving average price is $121.58. The company has a market cap of $13.21 billion, a PE ratio of 45.26, a price-to-earnings-growth ratio of 1.32 and a beta of 0.24. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.62). The business had revenue of $572.60 million for the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The business's revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.20 earnings per share. On average, analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.